Establishes a microfluidic platform to engineer breast cancer spheroids, suggesting a new approach for drug screening.
values, respectively), highlighting the functional significance of stromal interactions in recapitulating clinically relevant drug response within the model. Collectively, this study establishes a biomaterial-driven microfluidic platform for engineering TME-mimicking breast cancer spheroids, offering a robust and scalable approach for preclinical drug screening and the development of personalized cancer organoid models.
No takes yet. Share an insight, caveat, or question.
Ghosh et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: